Last reviewed · How we verify
NCT06817187
Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine
Phase 3 trial testing 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) in Streptococcus Pneumoniae Infections in 1,110 participants. Completed in 13 March 2024.
13 March 2024
Quick facts
| Lead sponsor | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,110 |
| Start date | 16 September 2021 |
| Primary completion | 13 March 2024 |
| Estimated completion | 13 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
- 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
- Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) — full drug profile →
Conditions studied
- Streptococcus Pneumoniae Infections — all drugs for Streptococcus Pneumoniae Infections →
Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — full company profile →
Who can join
Adults 3 Months to 3 Months, any sex, with Streptococcus Pneumoniae Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study aims to evaluate the mutual influence of combined administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine in the target population
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06817187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT06703203 — Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine · Phase 1, PHASE2 · completed
- NCT06970756 — A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60 · Phase 1 · not yet recruiting
- NCT06838195 — Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine · Phase 3 · active not recruiting
- NCT06344065 — Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants · Phase 3 · recruiting
- NCT06314880 — Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06817187 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
- Last refreshed: 10 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06817187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing